Viking Therapeutics completed enrollment in its Phase 3 VANQUISH-2 trial for obesity drug VK2735. The study will assess the weekly injection's safety and efficacy over 78 weeks, challenging Novo Nordisk's Ozempic dominance. Shares dipped 1% pre-market as retail sentiment on Stocktwits remained bearish.